More people with diabetes are moving towards wearables and virtual care, accelerated by the coronavirus pandemic, a survey conducted in the US has found.
Pump makers Insulet and Tandem have reported solid results for 2020, and both companies expect that momentum to continue, while Medtronic has a renewed focus on diabetes tech.
The survey, by SVB Leerink, reported that adoption among patients with Type 1 diabetes is projected to grow from 51% in 2021 to 62% in 2024.
SVB Leerink commissioned MEDACorp to survey 101 endocrinologists and nurse practitioners, representing 124,847 diabetes patients. The group is a global network of healthcare professionals and part of SVB Leerink.
Adoption among insulin-intensive Type 2 patients is projected to grow from 17% in 2021 to 23% in 2024.
Read more HERE.
